Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...

PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) ...

Novartis announced topline results from a pre-specified interim analysis of the phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically ...

(RTTNews) - Swiss drug major Novartis AG (NVS) announced Monday positive topline results from a pre-specified interim analysis of the Phase III PSMAddition trial for Pluvicto plus hormone therapy ...

Dr Petros Grivas discusses updates in biomarker-driven therapies and emerging treatment strategies from the STAMPEDE, AMPLITUDE, and PSMAddition trials.

Petros Grivas, MD, shares key updates from ASCO 2025, focusing on advances in prostate cancer across disease stages. He highlights promising results from the AMPLITUDE trial showing a radiographic ...

Novartis Says Phase III PSMAddition Trial Met Its Primary Endpoint. Published: June 2, 2025 at 1:39 a.m. ET. Share. Resize. About Dow Jones Newswires.

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...

In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT). Almost all mHSPC patients ultimately progress to metastatic ...

Novartis Pharma AG. Ad hoc announcement pursuant to Art. 53 LR. At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit ...

Novartis Pharma AG. Ad hoc announcement pursuant to Art. 53 LR. At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for ...